Brii Biosciences Limited
BRIBF
$0.2406
$0.00944.07%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,614.34% | -1,626.34% | -42.93% | -40.77% | 110.86% |
| Total Depreciation and Amortization | -64.27% | -63.98% | -31.34% | -32.38% | -20.03% |
| Total Amortization of Deferred Charges | 0.00% | 1.08% | -- | -- | -1.76% |
| Total Other Non-Cash Items | 190.71% | 191.44% | 127.34% | 126.93% | -524.71% |
| Change in Net Operating Assets | 58.09% | 57.76% | -- | -- | -54.32% |
| Cash from Operations | 38.54% | 38.05% | 38.24% | 39.17% | -4.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.13% | 104.75% | 208.06% | 206.43% | 114.51% |
| Cash from Investing | 102.13% | 103.75% | 207.85% | 206.22% | 114.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 29.84% | 29.84% | 25.38% | 25.38% | -0.56% |
| Issuance of Common Stock | -79.59% | -79.59% | -66.92% | -66.92% | -98.87% |
| Repurchase of Common Stock | 81.07% | 81.07% | -- | -- | -71.39% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -473.75% | -473.75% | -289.37% | -289.37% | 35.31% |
| Cash from Financing | 19.25% | 18.61% | 10.52% | 11.87% | -296.49% |
| Foreign Exchange rate Adjustments | -422.22% | -426.43% | -68.29% | -68.77% | -100.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16,059.88% | 16,192.61% | 122.93% | 122.58% | 100.12% |